In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100
- 1 October 1987
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 6 (5) , 559-563
- https://doi.org/10.1007/bf02014246
Abstract
BMY-28100 was compared with cephalexin, cefaclor, cefixime, and cefteram and found to be more active than the reference cephalosporins against Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus faecalis,and Clostridium difficile.BMY-28100 was the next most active, after cefteram, against Streptococcus pyogenes and Streptococcus pneumoniae.Against gram-negative bacteria, BMY-28100 showed similar activity to that of cefaclor. The antimicrobial activity of BMY-28100, including bactericidal activity, against Staphylococcus aureus was less affected by penicillinase-production than was that of cefaclor. BMY-28100 was more stable than cefaclor against various types of penicillinases, especially against the penicillinase from Staphylococcus aureus.Keywords
This publication has 5 references indexed in Scilit:
- Comparative in vitro activity of the new oral cephalosporin BMY-28100European Journal of Clinical Microbiology & Infectious Diseases, 1987
- BMY 28100, a new oral cephalosporinAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074)Antimicrobial Agents and Chemotherapy, 1986
- Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporinAntimicrobial Agents and Chemotherapy, 1984
- Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacaeAntimicrobial Agents and Chemotherapy, 1980